Bugybayeva D, Dumkliang E, Patil V, Yadagiri G, Suresh R, Singh M
Vaccines (Basel). 2024; 12(6).
PMID: 38932376
PMC: 11209417.
DOI: 10.3390/vaccines12060647.
Pallett S, Heskin J, Keating F, Mazzella A, Taylor H, Patel A
Commun Med (Lond). 2023; 3(1):83.
PMID: 37328651
PMC: 10275930.
DOI: 10.1038/s43856-023-00303-y.
de Oliveira J, Zhao Z, Xiang Y, Shin M, Villasenor K, Deng X
Front Microbiol. 2023; 14:1117494.
PMID: 37152732
PMC: 10157238.
DOI: 10.3389/fmicb.2023.1117494.
Singh G, Abbad A, Tcheou J, Mendu D, Firpo-Betancourt A, Gleason C
J Infect Dis. 2023; 228(5):564-575.
PMID: 37104046
PMC: 10469125.
DOI: 10.1093/infdis/jiad116.
Hajilooi M, Keramat F, Moazenian A, Rastegari-Pouyani M, Solgi G
Med Microbiol Immunol. 2023; 212(3):203-220.
PMID: 37103583
PMC: 10133916.
DOI: 10.1007/s00430-023-00763-y.
RBD and Spike DNA-Based Immunization in Rabbits Elicited IgG Avidity Maturation and High Neutralizing Antibody Responses against SARS-CoV-2.
da Costa H, Orts D, Moura A, Duarte-Neto A, Cirqueira C, Ressio R
Viruses. 2023; 15(2).
PMID: 36851769
PMC: 9959588.
DOI: 10.3390/v15020555.
SARS-CoV-2 vaccines: Potential refinements through induction of mucosal and trained immunity.
Portilho A, Gimenes Lima G, De Gaspari E
Clinics (Sao Paulo). 2022; 77:100057.
PMID: 35679760
PMC: 9148925.
DOI: 10.1016/j.clinsp.2022.100057.
Avidity of IgG to SARS-CoV-2 RBD as a Prognostic Factor for the Severity of COVID-19 Reinfection.
Manuylov V, Burgasova O, Borisova O, Smetanina S, Vasina D, Grigoriev I
Viruses. 2022; 14(3).
PMID: 35337024
PMC: 8949074.
DOI: 10.3390/v14030617.
Poor neutralization and rapid decay of antibodies to SARS-CoV-2 variants in vaccinated dialysis patients.
Bassi J, Giannini O, Silacci-Fregni C, Pertusini L, Hitz P, Terrot T
PLoS One. 2022; 17(2):e0263328.
PMID: 35143540
PMC: 8830698.
DOI: 10.1371/journal.pone.0263328.
Clinical Evaluation of Siemens SARS-CoV-2 Total Antibody assay and IgG assay using the Dimension EXL 200 in the Tokyo Metropolitan area.
Igawa G, Yamamoto T, Baba Y, Shinozuka K, Yuri M, Wakita M
Heliyon. 2021; 7(11):e08393.
PMID: 34805572
PMC: 8592641.
DOI: 10.1016/j.heliyon.2021.e08393.
Discovery Proteomics for COVID-19: Where We Are Now.
McArdle A, Washington K, Chazarin Orgel B, Binek A, Manalo D, Rivas A
J Proteome Res. 2021; 20(10):4627-4639.
PMID: 34550702
PMC: 8482317.
DOI: 10.1021/acs.jproteome.1c00475.
Unmethylated CpG motif-containing genomic DNA fragments of bacillus calmette-guerin improves immune response towards a DNA vaccine for COVID-19.
Zhou Z, Zhang X, Li Q, Fu L, Wang M, Liu S
Vaccine. 2021; 39(41):6050-6056.
PMID: 34521552
PMC: 8413458.
DOI: 10.1016/j.vaccine.2021.08.103.
Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection.
Portilho A, Silva V, Ahagon C, Matsuda E, de Oliveira E, da Silveira E
J Med Virol. 2021; 94(1):178-185.
PMID: 34428312
PMC: 8661980.
DOI: 10.1002/jmv.27290.
Vaccination versus infection with SARS-CoV-2: Establishment of a high avidity IgG response versus incomplete avidity maturation.
Struck F, Schreiner P, Staschik E, Wochinz-Richter K, Schulz S, Soutschek E
J Med Virol. 2021; 93(12):6765-6777.
PMID: 34387884
PMC: 8427118.
DOI: 10.1002/jmv.27270.
BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.
Pratesi F, Caruso T, Testa D, Tarpanelli T, Gentili A, Gioe D
Vaccines (Basel). 2021; 9(6).
PMID: 34207300
PMC: 8234791.
DOI: 10.3390/vaccines9060672.
Experimental studies using OMV in a new platform of SARS-CoV-2 vaccines.
Gaspar E, Prudencio C, De Gaspari E
Hum Vaccin Immunother. 2021; 17(9):2965-2968.
PMID: 33950776
PMC: 8108191.
DOI: 10.1080/21645515.2021.1920272.